Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Immunotherapy Resistance by Inflammation-Induced Dedifferentiation.

Mehta A, Kim YJ, Robert L, Tsoi J, Comin-Anduix B, Berent-Maoz B, Cochran AJ, Economou JS, Tumeh PC, Puig-Saus C, Ribas A.

Cancer Discov. 2018 Aug;8(8):935-943. doi: 10.1158/2159-8290.CD-17-1178. Epub 2018 Jun 13.

PMID:
29899062
2.

MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy.

Reinhardt J, Landsberg J, Schmid-Burgk JL, Ramis BB, Bald T, Glodde N, Lopez-Ramos D, Young A, Ngiow SF, Nettersheim D, Schorle H, Quast T, Kolanus W, Schadendorf D, Long GV, Madore J, Scolyer RA, Ribas A, Smyth MJ, Tumeh PC, Tüting T, Hölzel M.

Cancer Res. 2017 Sep 1;77(17):4697-4709. doi: 10.1158/0008-5472.CAN-17-0395. Epub 2017 Jun 26.

3.

Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration.

Lee JM, Lee MH, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE, Schaue D, Wang G, Rosen F, Yanagawa J, Walser TC, Lin Y, Park SJ, Adams S, Marincola FM, Tumeh PC, Abtin F, Suh R, Reckamp KL, Lee G, Wallace WD, Lee S, Zeng G, Elashoff DA, Sharma S, Dubinett SM.

Clin Cancer Res. 2017 Aug 15;23(16):4556-4568. doi: 10.1158/1078-0432.CCR-16-2821. Epub 2017 May 3.

4.

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.

Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N, Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Banayan N, Osorio JC, Nguyen-Kim DL, Chang J, Shintaku IP, Boasberg PD, Taylor EJ, Munster PN, Algazi AP, Chmielowski B, Dummer R, Grogan TR, Elashoff D, Hwang J, Goldinger SM, Garon EB, Pierce RH, Daud A.

Cancer Immunol Res. 2017 May;5(5):417-424. doi: 10.1158/2326-6066.CIR-16-0325. Epub 2017 Apr 14.

5.

Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma.

Nowicki TS, Akiyama R, Huang RR, Shintaku IP, Wang X, Tumeh PC, Singh A, Chmielowski B, Denny C, Federman N, Ribas A.

Cancer Immunol Res. 2017 Feb;5(2):118-126. doi: 10.1158/2326-6066.CIR-16-0148. Epub 2016 Dec 30.

6.

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.

Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, Palaskas N, Rodriguez GA, Parisi G, Azhdam A, Chmielowski B, Cherry G, Seja E, Berent-Maoz B, Shintaku IP, Le DT, Pardoll DM, Diaz LA Jr, Tumeh PC, Graeber TG, Lo RS, Comin-Anduix B, Ribas A.

Cancer Discov. 2017 Feb;7(2):188-201. doi: 10.1158/2159-8290.CD-16-1223. Epub 2016 Nov 30.

7.

Enhanced skin toxicity with concurrent ipilimumab and radiation in vaginal/vulvar melanoma: a case report and literature review.

Mesko S, Konecny GE, Tumeh PC, Kamrava M.

BJR Case Rep. 2016 Jul 29;3(1):20160002. doi: 10.1259/bjrcr.20160002. eCollection 2017.

8.

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A.

N Engl J Med. 2016 Sep 1;375(9):819-29. doi: 10.1056/NEJMoa1604958. Epub 2016 Jul 13.

9.

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials.

Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, Lyerly HK, Maecker H, Marabelle A, Melenhorst J, Miller J, Melero I, Odunsi K, Palucka K, Peoples G, Ribas A, Robins H, Robinson W, Serafini T, Sondel P, Vivier E, Weber J, Wolchok J, Zitvogel L, Disis ML, Cheever MA; Cancer Immunotherapy Trials Network (CITN).

J Immunother Cancer. 2016 Mar 15;4:15. doi: 10.1186/s40425-016-0118-0. eCollection 2016. Review.

10.

PD-1 Blockade Expands Intratumoral Memory T Cells.

Ribas A, Shin DS, Zaretsky J, Frederiksen J, Cornish A, Avramis E, Seja E, Kivork C, Siebert J, Kaplan-Lefko P, Wang X, Chmielowski B, Glaspy JA, Tumeh PC, Chodon T, Pe'er D, Comin-Anduix B.

Cancer Immunol Res. 2016 Mar;4(3):194-203. doi: 10.1158/2326-6066.CIR-15-0210. Epub 2016 Jan 19.

11.

PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A.

Nature. 2014 Nov 27;515(7528):568-71. doi: 10.1038/nature13954.

12.

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes.

Robert L, Harview C, Emerson R, Wang X, Mok S, Homet B, Comin-Anduix B, Koya RC, Robins H, Tumeh PC, Ribas A.

Oncoimmunology. 2014 Jun 25;3:e29244. eCollection 2014.

13.

The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade.

Ribas A, Tumeh PC.

Clin Cancer Res. 2014 Oct 1;20(19):4982-4. doi: 10.1158/1078-0432.CCR-14-0933. Epub 2014 Jun 26.

14.

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A.

N Engl J Med. 2013 Jul 11;369(2):134-44. doi: 10.1056/NEJMoa1305133. Epub 2013 Jun 2.

15.

Cancer therapy: Tumours switch to resist.

Ribas A, Tumeh PC.

Nature. 2012 Oct 18;490(7420):347-8. doi: 10.1038/nature11489. Epub 2012 Oct 10. No abstract available.

16.

BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.

Koya RC, Mok S, Otte N, Blacketor KJ, Comin-Anduix B, Tumeh PC, Minasyan A, Graham NA, Graeber TG, Chodon T, Ribas A.

Cancer Res. 2012 Aug 15;72(16):3928-37. doi: 10.1158/0008-5472.CAN-11-2837. Epub 2012 Jun 12.

17.

Characteristic purpura of the ears, vasculitis, and neutropenia--a potential public health epidemic associated with levamisole-adulterated cocaine.

Chung C, Tumeh PC, Birnbaum R, Tan BH, Sharp L, McCoy E, Mercurio MG, Craft N.

J Am Acad Dermatol. 2011 Oct;65(4):722-725.e2. doi: 10.1016/j.jaad.2010.08.024. Epub 2011 Jun 11.

18.

The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy.

Tumeh PC, Koya RC, Chodon T, Graham NA, Graeber TG, Comin-Anduix B, Ribas A.

J Immunother. 2010 Oct;33(8):759-68. doi: 10.1097/CJI.0b013e3181f1d644.

19.

PET imaging of cancer immunotherapy.

Tumeh PC, Radu CG, Ribas A.

J Nucl Med. 2008 Jun;49(6):865-8. doi: 10.2967/jnumed.108.051342. Review.

20.
21.

Structural and functional imaging correlates for age-related changes in the brain.

Tumeh PC, Alavi A, Houseni M, Greenfield A, Chryssikos T, Newberg A, Torigian DA, Moonis G.

Semin Nucl Med. 2007 Mar;37(2):69-87. Review.

PMID:
17289456
22.

Synthesis and biologic studies of iodinated (125I/127I) ethidium.

Ho N, Tumeh PC, Kassis AI.

Nucl Med Biol. 2001 Nov;28(8):983-90.

PMID:
11711318

Supplemental Content

Loading ...
Support Center